Business
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
DURHAM, N.C., March 20, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet diseases, presents preclinical data supporting repeat dosing of PBGENE-HBV in the ELIMINATE-B trial to treat patients with chronic HBV. Even with today’s standard of care, an estimated 15% to 40% of patients with HBV infections may develop complications, such as cirrhosis, liver fai
About this update from Precision Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/3f0eca60368e523414fa5a07a37131ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dJYvPUtHZ88u6dz1I67sTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3f0eca60368e523414fa5a07a37131ff","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_AxIuRHLsPD.vKj.Qnwscw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/3f0eca60368e523414fa5a07a37131ff","width":1024,"height":512}},"lazy":false},{"type":"text","content":"- PBGENE-HBV, the first and only clinical stage gene editing therapy for chronic hepatitis B –","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"- Repeat dosing of PBGENE-HBV supported by definitive preclinical safety and toxicology studies -","length":97,"tagName":"p","attribs":{}},{"type":"text","content":"- ELIMINATE-B global Phase 1 study for chronic hepatitis B actively enrolling patients and will evaluate up to three dose administrations of PBGENE-HBV at each dose level –","length":172,"tagName":"p","attribs":{}},{"type":"text","content":"- Precision remains on track to continue reporting clinical data throughout 2025 –","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C., March 20, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet diseases, presents preclinical data supporting repeat dosing of PBGENE-HBV in the ELIMINATE-B trial to treat patients with chronic HBV. Even with today’s standard of care, an estimated 15% to 40% of patients with HBV infections may develop complications, such as cirrhosis, liver failure, or liver cancer (hepatocellular carcinoma), which account for the majority of the 1.1 million global HBV-related deaths each year. These data will be presented during an oral presentation at the Global Hepatitis Summit (GHS) 2025, being held March 18-21, 2025, in Los Angeles, California.","length":811,"tagName":"p"},{"type":"text","content":""We are excited to share new support...